Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F11%3A00369512" target="_blank" >RIV/86652036:_____/11:00369512 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s10456-011-9213-5" target="_blank" >http://dx.doi.org/10.1007/s10456-011-9213-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10456-011-9213-5" target="_blank" >10.1007/s10456-011-9213-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress

Popis výsledku v původním jazyce

Cancer cells produce galectin-1 as a tumor promoting protein. Thiodigalactoside (TDG) as a non-metabolised drug, is shown to suppress tumor growth by inhibiting cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesisand protection against oxidative stress. Using B16F10 melanoma and 4T1 orthotopic breast cancer models, intratumoral injection of TDG significantly raised the levels of infiltrating CD8(+) lymphocytes and reduced CD31(+) endothelial cell content, reducing tumor growth. TDG treatment of tumors in Balb/c nude mice reduced angiogenesis and slowed tumor growth by a third less than in immunocompetent mice. Knocking down galectin-1 expression (G1KD) significantly impeded tumor growth and the sensitivity of the G1KD tumors to TDG was severely reduced. Endothelial cells were protected by galectin-1 from oxidative stress-induced apoptosis, but TDG inhibited this antioxidant protective effect of galectin-1 and reduced tube forming activity.

Název v anglickém jazyce

Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress

Popis výsledku anglicky

Cancer cells produce galectin-1 as a tumor promoting protein. Thiodigalactoside (TDG) as a non-metabolised drug, is shown to suppress tumor growth by inhibiting cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesisand protection against oxidative stress. Using B16F10 melanoma and 4T1 orthotopic breast cancer models, intratumoral injection of TDG significantly raised the levels of infiltrating CD8(+) lymphocytes and reduced CD31(+) endothelial cell content, reducing tumor growth. TDG treatment of tumors in Balb/c nude mice reduced angiogenesis and slowed tumor growth by a third less than in immunocompetent mice. Knocking down galectin-1 expression (G1KD) significantly impeded tumor growth and the sensitivity of the G1KD tumors to TDG was severely reduced. Endothelial cells were protected by galectin-1 from oxidative stress-induced apoptosis, but TDG inhibited this antioxidant protective effect of galectin-1 and reduced tube forming activity.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Angiogenesis

ISSN

0969-6970

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

15

Strana od-do

293-307

Kód UT WoS článku

000293922300007

EID výsledku v databázi Scopus

—